Obesity Planned News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

/PRNewswire/ Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies.

Ligand pharmaceuticals incorporatedDrug administrationTherapeutics incPlacebo adjusted mean weight lossObserved afterDay studyFlow ratesRelated adverseObesity plannedCall scheduledViking therapeuticsBrian lianBody weight followingDaily dosingRelated adverse events followingLigand pharmaceuticals

Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Therapeutics incLigand pharmaceuticals incorporatedExchange commissionPositive top line resultsMedian liver fat reductionBiopsy results expectedObesity plannedResults expectedQuarter end cash positionViking therapeuticsQuarter endedRecent corporateObese patients plannedPositive phaseDemonstrating significant weight lossPromising safety

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735

/PRNewswire/ Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for.

Drug administrationLigand pharmaceuticals incorporatedPrnewswire viking therapeutics incTherapeutics incPlacebo adjusted mean weight lossFrom baselineObserved afterObesity plannedBrian lianBody weight followingReported adverse events followingViking therapeuticsLigand pharmaceuticals